translation agency

AIDS Weekly Plus
New Findings in Gene Therapy Described from Inovio Pharmaceuticals
Staff Writer
October 29, 2012


2012 OCT 29 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Fresh data on Gene Therapy are presented in a new report. According to news reporting from Blue Bell, Pennsylvania, by NewsRx journalists, research stated, "DNA represents an ideal vaccine platform for HIV and many infectious diseases because of its safety, stability, and ease of manufacture. However, the immunogenicity of DNA vaccines has traditionally been low compared with viral vectors, recombinant protein, and live attenuated vaccines."

The news correspondents obtained a quote from the research from Inovio Pharmaceuticals, "The immunogenicity of DNA vaccines has been significantly enhanced by delivery with in vivo electroporation. Further improvements now allow electroporation to be performed in the dermis, which could potentially improve patient tolerability and may further enhance immunogenicity. In this study we examined how the current of intradermal vaccination impacts antigen expression, inflammation, and the induction of both humoral and cellular immunity in guinea pigs and nonhuman primates. We observed that a lower (0.1 A) current reduced inflammation and improved antigen expression compared with a 0.2 A current. The improved antigen expression resulted in a trend toward higher cellular immune responses but no impact on HIV- and influenza-specific binding titers. This study highlights the need for optimization of electroporation conditions in vivo in order to balance enhanced plasmid transfection with a loss of expression due to tissue inflammation and necrosis."

According to the news reporters, the research concluded: "These results suggest that a lower, 0.1-A current may not only improve patient tolerability but also improve immunogenicity."

For more information on this research see: Intradermal DNA Vaccination Enhanced by Low-Current Electroporation Improves Antigen Expression and Induces Robust Cellular and Humoral Immune Responses. Human Gene Therapy, 2012;23(9):943-950. Human Gene Therapy can be contacted at: Mary Ann Liebert Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Human Gene Therapy - www.liebertpub.com/overview/human-gene-therapy-and-part-b-methods/19/)

Our news journalists report that additional information may be obtained by contacting N.A. Hutnick, Inovio Pharmaceut, Blue Bell, PA 19422, United States (see also Gene Therapy).

Keywords for this news article include: Blue Bell, Pennsylvania, DNA Research, Gene Therapy, United States, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC

www.aegis.org